
formylmethionine
What is it
N-formylmethionine (fMet) is a modified form of the amino acid methionine in which a formyl group is attached to the amino group. It serves as the initiator amino acid for protein synthesis in bacteria, mitochondria, and chloroplasts (but not in cytoplasmic protein synthesis in human cells).
Evidence for 2 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Biological role (research)
Essential to bacterial and mitochondrial protein synthesis (biology, not a supplement benefit).
Supplemental use
No documented therapeutic benefit from oral supplementation.
How it works
Dosage
When and how to take it
1 commercial form
Compare the main delivery options and what they’re best suited for.
N-formyl-L-methionine (research)
Primarily a research compound.
Not used as a consumer supplement.
Safety
Who should be cautious
Interactions
Frequently asked questions
Is formylmethionine a useful supplement?⌄
No. It has no documented therapeutic benefit and is primarily a biochemistry research compound.
What does it do in the body?⌄
It is the starting amino acid for protein synthesis in bacteria and mitochondria. Free fMet peptides from infections act as inflammatory signals.
References
formylmethionine on Wikidata — Wikidata link
formylmethionine (ChEBI:182822) — ChEBI link
formylmethionine (PubChem CID 911) — PubChem link
formylmethionine on NIH DSLD (US supplement label database) — NIH Dietary Supplement Label Database link
Research on formylmethionine (PubMed search) — PubMed link
Track formylmethionine with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.
